Welcome to our dedicated page for Progyny news (Ticker: PGNY), a resource for investors and traders seeking the latest updates and insights on Progyny stock.
Progyny, Inc. (Nasdaq: PGNY) is a leading fertility and family building benefits company that integrates service, science, technology, and data to provide comprehensive fertility solutions for self-insured employers. The company's unique approach offers members tailored, value-based treatment plans, leveraging the latest medical advancements to improve outcomes, shorten the time to pregnancy, and reduce fertility-related costs.
Progyny's benefit plans encompass a wide range of fertility solutions, including IVF (In Vitro Fertilization), IUI (Intrauterine Insemination), embryo banking, egg freezing, adoption, and surrogacy. These plans are supported by Progyny's network of high-quality fertility specialists, known for their expertise in performing Smart Cycle treatments.
Headquartered in New York City, Progyny has established itself as a transformative leader in the fertility benefits space, partnering with employers across various industries. The company's clients benefit from a premier network of fertility and women's health specialists, advanced clinical outcomes, and reduced healthcare costs.
Progyny has been recognized for its leadership and growth, earning accolades from CNBC Disruptor 50, Modern Healthcare’s Best Places to Work in Healthcare, Forbes’ Best Employers, Financial Times, Inc. 5000, Inc. Power Partners, and Crain’s Fast 50 for NYC.
In the third quarter of 2023, Progyny reported having 392 clients, a significant increase from 282 clients in the same period in 2022. The company's financial performance includes positive Adjusted EBITDA, demonstrating robust profitability and financial health. Progyny continues to expand its services and partnerships, ensuring comprehensive support for patients and employers alike.
For more information, visit www.progyny.com. Investors can reach out to James Hart at investors@progyny.com, and media inquiries can be directed to Selena Yang at media@progyny.com.
Progyny, Inc. (Nasdaq: PGNY) will report its financial results for Q3 2022 on November 3, 2022, after market close. A conference call will follow at 4:45 P.M. ET, accessible via dialing 1-866-825-7331 (U.S.) or 1-973-413-6106 (international) with passcode 265484. An audio replay will be available until November 10, 2022. Progyny specializes in fertility benefits management, aiming to improve patient outcomes and reduce employer costs. The company has received multiple accolades, including recognition from CNBC Disruptor 50 and Modern Healthcare.
Progyny (Nasdaq: PGNY), a leader in fertility benefits management, announced that CEO Pete Anevski and CFO Mark Livingston will join a fireside chat at the BofA Securities 2022 Global Healthcare Conference on September 15, 2022, at 5:50 A.M. Eastern Time. This event aims to discuss Progyny's comprehensive fertility solutions which benefit employers, patients, and healthcare providers. Interested parties can access a live audiocast and replay on Progyny's website. The company has received multiple awards for its innovative approach to fertility benefits.
Progyny (Nasdaq: PGNY) announced the appointment of Lloyd Dean to its Board of Directors, effective August 30, 2022. Dean, the Chief Executive Emeritus of CommonSpirit Health, brings over 40 years of healthcare experience. Progyny's CEO, Pete Anevski, expressed confidence that Dean's expertise will enhance the company’s growth and leadership in fertility and family building benefits. Following this appointment, the Board now consists of ten members. Dean will serve on the Nominating and Corporate Governance Committee, focusing on expanding access to fertility solutions.
Progyny, Inc. (PGNY) reported record quarterly revenue of $195.0 million, reflecting a 52% growth from the prior year. Strong demand for fertility benefits led to a 37% increase in fertility services revenue, totaling $126.8 million, and an 87% surge in pharmacy services revenue, reaching $68.2 million. Despite a 53% decrease in net income, attributed to increased stock-based compensation, Adjusted EBITDA saw a 78% increase, reaching $32.9 million. The company raised its full-year guidance, projecting annual revenue between $750.0 million and $775.0 million.
Progyny's Clinical Outcomes Exceed National Benchmarks
Progyny (Nasdaq: PGNY), a leader in fertility benefits management, has achieved superior clinical outcomes validated by Milliman, Inc. Its independent evaluation confirms Progyny’s methodology for measuring and publishing fertility treatment successes against national benchmarks. Since 2016, Progyny has consistently delivered faster pregnancies, fewer miscarriages, and healthier outcomes compared to national averages. The company emphasizes transparency and aims to raise standards in fertility benefits as it continues to expand its network of high-quality providers.
Progyny (PGNY) will release its financial results for Q2 2022 on August 4, 2022, after market close. An investor conference call is scheduled for 4:45 PM ET. Participants in the U.S. can join by dialing 1-866-825-7331, with international access via 1-973-413-6106, using passcode 265484. A replay will be available until August 11, 2022. Progyny, recognized for its comprehensive fertility benefits, aims to provide optimal clinical outcomes and reduce healthcare costs.
Progyny, a leader in fertility and family building benefits, will have its CEO Pete Anevski and CFO Mark Livingston engage in a fireside chat at the Jefferies 2022 Healthcare Conference on June 8, 2022, at 10:30 A.M. Eastern Time. This event will be accessible via a live audiocast on Progyny’s website. The company’s innovative solutions are designed to empower patients and reduce healthcare costs for employers while achieving optimal clinical outcomes. Progyny is headquartered in New York City and has received numerous recognitions for its growth and leadership in the healthcare sector.
Progyny (Nasdaq: PGNY) has launched the AHA Grant™ in partnership with The Broken Brown Egg, aiming to provide education, financial assistance, and emotional support to individuals and couples of color facing infertility. Announced on May 6, 2022, the grant will support one recipient with financial aid for treatment, medication through partners like Alto Pharmacy and Ferring Pharmaceuticals, and guidance from a dedicated fertility coach. Applications are open until June 10, 2022, with the winner revealed in mid-July.
Progyny, Inc. (PGNY) reported record revenue of $172.2 million for Q1 2022, marking a 41% growth year-over-year. The company raised its full-year revenue guidance to $735 million to $775 million, anticipating 47% to 55% growth. Despite a 67% decline in net income to $5 million, adjusted EBITDA rose 44% to $24.8 million. Progyny experienced operational efficiencies, with a total of 264 clients and a significant increase in pharmacy benefit services revenue, reflecting a strong demand for fertility benefits.
FAQ
What is the current stock price of Progyny (PGNY)?
What is the market cap of Progyny (PGNY)?
What services does Progyny offer?
Who are Progyny's clients?
How does Progyny's approach improve fertility outcomes?
What recognition has Progyny received?
Where is Progyny headquartered?
How many clients did Progyny have in the third quarter of 2023?
What are the financial highlights of Progyny for the third quarter of 2023?
How can investors and media contact Progyny?
What is the Smart Cycle treatment?
What makes Progyny's benefits solution unique?
